Plasma Cannabinoid Pharmacokinetics following Controlled Oral Δ9-Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration
Open Access
- 1 January 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 57 (1), 66-75
- https://doi.org/10.1373/clinchem.2010.152439
Abstract
BACKGROUND: Sativex®, a cannabis extract oromucosal spray containing Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), is currently in phase III trials as an adjunct to opioids for cancer pain treatment, and recently received United Kingdom approval for treatment of spasticity. There are indications that CBD modulates THC's effects, but it is unclear if this is due to a pharmacokinetic and/or pharmacodynamic interaction. METHODS: Cannabis smokers provided written informed consent to participate in this randomized, controlled, double-blind, double-dummy institutional review board–approved study. Participants received 5 and 15 mg synthetic oral THC, low-dose (5.4 mg THC and 5.0 mg CBD) and high-dose (16.2 mg THC and 15.0 mg CBD) Sativex, and placebo over 5 sessions. CBD, THC, 11-hydroxy-THC, and 11-nor- 9-carboxy-THC were quantified in plasma by 2-dimensional GC-MS. Lower limits of quantification were ≤0.25 μg/L. RESULTS: Nine cannabis smokers completed all 5 dosing sessions. Significant differences (P < 0.05) in maximum plasma concentrations (Cmax) and areas under the curve from 0–10.5 h postdose (AUC0→10.5) for all analytes were found between low and high doses of synthetic THC and Sativex. There were no statistically significant differences in Cmax, time to maximum concentration or in the AUC0→10.5 between similar oral THC and Sativex doses. Relative bioavailability was calculated to determine the relative rate and extent of THC absorption; 5 and 15 mg oral THC bioavailability was 92.6% (13.1%) and 98.8% (11.0%) of low- and high-dose Sativex, respectively. CONCLUSION: These data suggest that CBD modulation of THC's effects is not due to a pharmacokinetic interaction at these therapeutic doses.Keywords
Funding Information
- National Institutes of Health
This publication has 25 references indexed in Scilit:
- Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in plasmaAnalytical and Bioanalytical Chemistry, 2010
- Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related PainJournal of Pain and Symptom Management, 2010
- Randomized Placebo-Controlled Double-Blind Clinical Trial of Cannabis-Based Medicinal Product (Sativex) in Painful Diabetic NeuropathyDiabetes Care, 2009
- Effect of Sublingual Application of Cannabinoids on Intraocular Pressure: A Pilot StudyJournal of Glaucoma, 2006
- Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trialPain, 2004
- Marijuana and Medicine: Assessing the Science Base: A Summary of the 1999 Institute of Medicine ReportArchives of General Psychiatry, 2000
- Characterization of Cytochrome P450 3A Inactivation by Cannabidiol: Possible Involvement of Cannabidiol-Hydroxyquinone as a P450 InactivatorChemical Research in Toxicology, 1998
- Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administrationJournal of Mass Spectrometry, 1986
- Single dose kinetics of deuterium labelled Δ1-tetrahydrocannabinol in heavy and light cannabis usersJournal of Mass Spectrometry, 1982
- Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in manJournal of Pharmacokinetics and Biopharmaceutics, 1981